NCT00338988View on ClinicalTrials.gov

Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma

PHASE2CompletedINTERVENTIONAL

Enrollment

44

Participants

Timeline

Start Date

August 31, 2003

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions

Cancer of the GallbladderCancer of the Biliary Tract

Interventions

DRUG

Capecitabine

1500 mg/m\^2 PO twice daily x 14 days.

DRUG

Oxaliplatin

130 mg/m\^2 IV over 2 hours on day 1 of cycle.

Trial Locations (1)

77030

U.T. M.D. Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Sanofi-Synthelabo

All Listed Sponsors

collaborator

Sanofi-Synthelabo

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER